Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Neuronal-associated microtubule proteins class III beta-tubulin and MAP2c in neuroblastoma: role in resistance to microtubule-targeted drugs.

Molecular cancer therapeutics - 1 Sept 2004

Don Sima, Verrills Nicole M, Liaw Tracy Y E, Liu Marjorie L M, Norris Murray D, Haber Michelle, Kavallaris Maria

Abstract excerpt

Advanced stage neuroblastoma has a poor clinical outcome and microtubule-destabilizing agents, such as the Vinca alkaloids, are an important component in the treatment of this childhood cancer. Vinca alkaloids bind to beta-tubulin on the alpha/beta-tubulin heterodimer and disrupt microtubule dyna...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Microtubule-Associated Proteins
Share to Microtubule Proteins

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Microtubules

Share to Neuroblastoma

Share to Paclitaxel

Share to Phosphoproteins

Share to Stathmin

Share to Tubulin

Source

Identifiers

PMID: 15367708

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026. Prepared record publication-15367708-2026-09-02.2. Manifest publication-graph-cohort-2026-09-02.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Neuronal-associated microtubule proteins class III beta-tubulin and MAP2c in neuroblastoma: role in resistance to microtubule-targeted drugs.PMID 15367708Read ↗

Multiple microtubule alterations are associated with Vinca alkaloid resistance in human leukemia cells.Semantic proximity Read ↗

Microtubule inhibitors: Differentiating tubulin-inhibiting agents based on mechanisms of action, clinical activity, and resistanceSemantic proximity Read ↗

Microtubules: A dynamic target in cancer therapySemantic proximity Read ↗

Cancer cells acquire mitotic drug resistance properties through beta I-tubulin mutations and alterations in the expression of beta-tubulin isotypes.Semantic proximity Read ↗

Class I beta-tubulin mutations in 2-methoxyestradiol-resistant acute lymphoblastic leukemia cells: implications for drug-target interactions.Semantic proximity Read ↗

Alterations in gamma-actin and tubulin-targeted drug resistance in childhood leukemia.Semantic proximity Read ↗

Microtubules and Cell Division: Potential Pharmacological Targets in Cancer TherapySemantic proximity Read ↗

Microtubule alterations and resistance to tubulin-binding agents (Review)Semantic proximity Read ↗

Mutations in alpha- and beta-tubulin that stabilize microtubules and confer resistance to colcemid and vinblastine.Semantic proximity Read ↗

Enhanced stability of microtubules contributes in the development of colchicine resistance in MCF-7 cells.Semantic proximity Read ↗

A proteomic investigation into etoposide chemo‐resistance of neuroblastoma cell linesSemantic proximity Read ↗

Class III β-tubulin expression and in vitro resistance to microtubule targeting agentsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.